Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Sawai Announces Revised 3-year Management Plan
February 28, 2005
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 28, 2005
- MREAC to Begin Improving Education, Training System
February 28, 2005
- BULLETIN
February 28, 2005
- Fujisawa to Transfer Marketing of 11 Products to 3 Companies
February 28, 2005
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
February 28, 2005
- Daiichi Suntory Transfer Sales of Farom to Maruho
February 28, 2005
- Meet the Leaders (40)
February 28, 2005
- BUSINESS NEWS IN BRIEF
February 28, 2005
- Sunrise Plan Aims at Sales of \360 Billion in 2010: Mr Nagayama of Chugai
February 28, 2005
- Transitional Period for Labeling Changes in Rx-only Drug Announced
February 28, 2005
- Korosho Issues Guide on Preparing Manufacturing Applications
February 28, 2005
- Drug Production Statistics Data to Be Reported More Promptly
February 28, 2005
- 2005 Will Be a Major Turning Point: Prefectural Health Officials Meeting
February 28, 2005
- BUSINESS NEWS IN BRIEF
February 21, 2005
- MEDICAL DEVICE NEWS IN BRIEF
February 21, 2005
- Alliance with PPD Enables Us to Meet Various Needs of Clients: Ms Oishi of CMIC
February 21, 2005
- 1st 3 Qtrs Business Results
February 21, 2005
- 1st 3 Qtrs Business Results
February 21, 2005
- Nippon Kayaku to Increase Focus on Oncology
February 21, 2005
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…